OCUL Quote, Financials, Valuation and Earnings

EyePoint Plc has a net margin of -487.96% compared to Ocular Therapeutix, Inc.'s net margin of -10904.68%. Ocular Therapeutix, Inc.'s return on equity of -73.88% beat EyePoint Plc's return on equity of -83.61%.

Ocular Therapeutix, Inc. has a consensus price target of $26.00, signalling upside risk potential of 206.24%. On the other hand EyePoint Plc has an analysts' consensus of $37.42 which suggests that it could grow by 179.23%. Given that Ocular Therapeutix, Inc. has higher upside potential than EyePoint Plc, analysts believe Ocular Therapeutix, Inc. is more attractive than EyePoint Plc.

Ocular Therapeutix, Inc. has a beta of 0.955, which suggesting that the stock is 4.517% less volatile than S&P 500. In comparison EyePoint Plc has a beta of 1.891, suggesting its more volatile than the S&P 500 by 89.146%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. EyePoint Plc pays out -- of its earnings as a dividend.

Ocular Therapeutix, Inc. quarterly revenues are $13.3M, which are larger than EyePoint Plc quarterly revenues of $620K. Ocular Therapeutix, Inc.'s net income of -$64.7M is higher than EyePoint Plc's net income of -$67.6M. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while EyePoint Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 31.24x versus 31.28x for EyePoint Plc. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -487.96% compared to Ocular Therapeutix, Inc.'s net margin of 21.74%. Ocular Therapeutix, Inc.'s return on equity of -73.88% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Ocular Therapeutix, Inc. has a consensus price target of $26.00, signalling upside risk potential of 206.24%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $872.70 which suggests that it could grow by 14.55%. Given that Ocular Therapeutix, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Ocular Therapeutix, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Ocular Therapeutix, Inc. has a beta of 0.955, which suggesting that the stock is 4.517% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.238%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.94 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ocular Therapeutix, Inc. quarterly revenues are $13.3M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Ocular Therapeutix, Inc.'s net income of -$64.7M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 31.24x versus 5.66x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals, Inc. has a net margin of -487.96% compared to Ocular Therapeutix, Inc.'s net margin of -82.97%. Ocular Therapeutix, Inc.'s return on equity of -73.88% beat Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34%.

Ocular Therapeutix, Inc. has a consensus price target of $26.00, signalling upside risk potential of 206.24%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $137.27 which suggests that it could grow by 59.08%. Given that Ocular Therapeutix, Inc. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Ocular Therapeutix, Inc. is more attractive than Rhythm Pharmaceuticals, Inc..

Ocular Therapeutix, Inc. has a beta of 0.955, which suggesting that the stock is 4.517% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 2.142, suggesting its more volatile than the S&P 500 by 114.237%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ocular Therapeutix, Inc. quarterly revenues are $13.3M, which are smaller than Rhythm Pharmaceuticals, Inc. quarterly revenues of $57.3M. Ocular Therapeutix, Inc.'s net income of -$64.7M is lower than Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 31.24x versus 28.95x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -487.96% compared to Ocular Therapeutix, Inc.'s net margin of 36.91%. Ocular Therapeutix, Inc.'s return on equity of -73.88% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.

Ocular Therapeutix, Inc. has a consensus price target of $26.00, signalling upside risk potential of 206.24%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $547.72 which suggests that it could grow by 24.85%. Given that Ocular Therapeutix, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Ocular Therapeutix, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Ocular Therapeutix, Inc. has a beta of 0.955, which suggesting that the stock is 4.517% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.363, suggesting its less volatile than the S&P 500 by 63.664%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ocular Therapeutix, Inc. quarterly revenues are $13.3M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Ocular Therapeutix, Inc.'s net income of -$64.7M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 28.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 31.24x versus 9.19x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.